Anika Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed orthopedic products company centered on hyaluronic-acid-based OA Pain Management and Regenerative Solutions. Its 8-K filings report operating and financial results, guidance updates, material events, clinical and regulatory disclosures for Hyalofast, and governance matters involving board and executive transitions.
Proxy materials describe shareholder voting matters, board structure, executive compensation, corporate governance practices, and the company’s focused portfolio following completed portfolio actions. The filings also identify ANIK common stock, capital-structure disclosures, risk and operating topics, and channel-based business reporting for Commercial Channel and OEM Channel activity.
Anika Therapeutics, Inc. (ANIK) reported third-quarter 2026 revenue of $30.6 million, up 10% from $27.8 million a year earlier; nine-month revenue was $92.8 million, up 13% from $82.2 million. Gross profit rose to $18.8 million from $15.6 million for the quarter and to $59.1 million from $44.6 million for nine months. Net loss narrowed to $0.3 million from $2.3 million for the quarter and to $2.1 million from $11.2 million for nine months.
The FDA notified the company that its current Hyalofast PMA application is not approvable, primarily based on clinical data; Anika continues discussions with the FDA about evidence that may support future approval. Anika targets a Cingal NDA submission by December 31, 2027; Chemistry, Manufacturing and Controls activities remain a key milestone, and approval remains subject to development and regulatory requirements.
Cash was $45.0 million at September 30, 2026, and nine-month operating cash flow was $2.8 million, versus $6.6 million a year earlier. An extended distributor agreement effective January 1, 2027 through December 31, 2036 carries expected payments of $8.0 million, including $4.0 million upfront in the first quarter of 2027 and $4.0 million tied to commercial volumes.
Anika Therapeutics, Inc. reported third-quarter 2026 revenue of $30.6 million, up 10% year over year. Commercial Channel revenue was $14.0 million, up 17%, and OEM Channel revenue was $16.6 million, up 5%. Gross margin was 62%, versus 56%; GAAP loss from continuing operations was $311,000, versus a $3.175 million loss.
Adjusted EBITDA was $5.1 million, versus $865,000. For the nine months ended September 30, 2026, operating cash flow was $2.847 million, versus $6.551 million; cash and equivalents were $45.0 million as of September 30, 2026. Anika entered a 10-year Hyvisc distribution partnership with Boehringer Ingelheim and expects $8 million in payments: $4 million upfront in first-quarter 2027 and $4 million tied to commercial volumes.
In October, the FDA notified Anika that the Hyalofast PMA application was not approvable, primarily based on clinical data; Anika is assessing regulatory pathways. Cingal study enrollment was completed in September, and an NDA submission is expected before year-end 2027 after the clinical study report and CMC work. 2026 guidance is 6%–10% total-company revenue growth and 15%–17% adjusted EBITDA margin, versus 5%–10% and 13%–17% previously; 2027 revenue growth guidance is flat to 5%.
ANIK received a notice of intended sale of 16,864 shares of its common stock to be sold on NASDAQ, with an aggregate market value of $355,255.47 as of 08/07/2026. This is disclosed under a Form 144 filing for proposed sales of restricted or control securities.
The filing also lists recent activity in the same securities: an open market purchase by the issuer of 2,700 shares for cash on 03/05/2024, and restricted stock vesting of 14,164 shares on 06/20/2026 as compensation.
Anika Therapeutics, Inc. director Gary P. Fischetti reported open-market purchases of company stock. On August 3 and 4, 2026, he bought 1,000 shares of Common Stock on each date at per-share prices of $20.745 and $20.315, respectively, for a total of 2,000 shares acquired directly.
Vanguard Capital Management LLC reports its institutional ownership position in Anika Therapeutics Inc common stock. Vanguard and certain affiliated entities beneficially own 659,216 shares, representing 4.95% of the class as of June 30, 2026. Vanguard has sole voting power over 87,103 shares and sole dispositive power over 659,216 shares, with no shared voting or dispositive power. The filing notes that these holdings include securities in Vanguard funds and managed accounts for which Vanguard affiliates exercise voting and/or dispositive authority, and that no other individual person has an interest in more than 5% of the class through these holdings.
Anika Therapeutics reported Q2 2026 revenue of $32.6 million, up 16% year over year, and net income from continuing operations of $3.3 million versus a loss a year ago. Gross margin rose to 65% from the low‑50% range, helped by higher OEM sales and better manufacturing utilization.
For the first half of 2026, revenue was $62.2 million and the net loss narrowed to $1.7 million. Cash and cash equivalents were $38.4 million with working capital of $77.0 million, and a new $50.0 million revolving credit facility, expandable to $100.0 million, remained undrawn. Customer concentration is high, with J&J MedTech contributing about half of revenue. The company continued FDA interactions on Cingal’s planned NDA and Hyalofast’s PMA review, while executing cost reductions and share repurchases totaling $30.0 million for 2.14 million shares since program inception.
Anika Therapeutics reported strong second-quarter 2026 results, with total revenue up 16% year over year to $32.6 million. Commercial Channel revenue grew 17% to a record $13.9 million and OEM Channel revenue rose 14% to $18.7 million. Gross profit increased to $21.2 million and gross margin expanded to 65%, helped by higher volumes, increased production and a favorable sales mix, while operating expenses were roughly flat at $18.3 million.
Income from continuing operations was $3.3 million, a 10% margin, and adjusted EBITDA reached $7.1 million, its highest level since 2020, with a 22% margin. Cash and equivalents were $38.4 million at June 30, 2026. Based on this performance, Anika raised 2026 guidance, now expecting total revenue growth of 5%–10% and an adjusted EBITDA margin of 13%–17%, and revised 2027 guidance under a new practice that excludes unapproved products, lowering Commercial Channel growth expectations to 5%–15%. The company also highlighted ongoing FDA review of the Hyalofast PMA and progress toward an NDA filing for Cingal.
BlackRock Portfolio Management LLC filed an amended ownership report for Anika Therapeutics Inc. common stock. The firm reported beneficial ownership of 544,710 shares, representing 4.1% of the outstanding common shares. It holds sole voting power over 520,622 shares and sole dispositive power over 544,710 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Anika’s outstanding common stock.
Anika Therapeutics, Inc. entered into a Fifth Amendment to its Credit Agreement with Bank of America, N.A. on July 10, 2026. The Amended Agreement provides a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031.
Subject to specified conditions and lender approval, Anika may request up to an additional $50.0 million in commitments for a maximum aggregate commitment of $100.0 million. Borrowings bear interest at SOFR plus 0.25%–1.25%, based on Anika’s consolidated leverage ratio. A 0.20%–0.30% annual commitment fee applies to the unused facility, payable quarterly in arrears. Loan origination costs are amortized over the five-year term. The facility includes customary covenants and events of default, with financial covenants tied to leverage and interest coverage, and is secured by a first priority lien on substantially all assets other than certain intangible assets.
Fischetti Gary P reported acquisition or exercise transactions in this Form 4 filing.
Anika Therapeutics director Gary P. Fischetti received a grant of 10,402 shares of common stock in the form of restricted stock units (RSUs). The award carried no cash purchase price and increases his direct holdings to 52,015 shares after the grant.
Each RSU represents a right to receive one share of Anika Therapeutics common stock. The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027, aligning the director’s compensation with long-term shareholder interests.